FDA reverses, plans to pull interchangeability statement from labels of interchangeable biosimilars
The FDA on Friday released new draft guidance that reverses prior guidance and says that interchangeable biosimilars should no longer include a description of their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
